Publication:
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.

Simple item page
dc.contributor.authorMartinez-Lopez, Joaquin
dc.contributor.authorAlonso, Rafael
dc.contributor.authorWong, Sandy W
dc.contributor.authorRios, Rafael
dc.contributor.authorShah, Nina
dc.contributor.authorRuiz-Heredia, Yanira
dc.contributor.authorSanchez-Pina, Jose Maria
dc.contributor.authorSanchez, Ricardo
dc.contributor.authorBahri, Natasha
dc.contributor.authorZamanillo, Irene
dc.contributor.authorPoza, Maria
dc.contributor.authorBuenache, Natalia
dc.contributor.authorEncinas, Cristina
dc.contributor.authorJuarez, Luis
dc.contributor.authorMiras, Fatima
dc.contributor.authorCollado, Luis
dc.contributor.authorBarrio, Santiago
dc.contributor.authorMartin, Thomas
dc.contributor.authorCedena, Maria Teresa
dc.contributor.authorWolf, Jeffrey
dc.date.accessioned2023-02-09T11:47:06Z
dc.date.available2023-02-09T11:47:06Z
dc.date.issued2021-08-17
dc.description.abstractThe assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retrospective study, we present the results from a multinational and multicenter series of 400 patients with MRD monitoring during front-line therapy with the aim of exploring how clinical decisions made based on those MRD results affected outcomes. As expected, achievement of MRD negativity at any point was associated with improved PFS versus persistent MRD positivity (median PFS 104 vs. 45 months, p 
dc.identifier.doi10.1186/s13045-021-01135-w
dc.identifier.essn1756-8722
dc.identifier.pmcPMC8369640
dc.identifier.pmid34404440
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369640/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s13045-021-01135-w
dc.identifier.urihttp://hdl.handle.net/10668/18386
dc.issue.number1
dc.journal.titleJournal of hematology & oncology
dc.journal.titleabbreviationJ Hematol Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.number126
dc.pubmedtypeLetter
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMeasurable residual disease
dc.subjectMinimal residual disease
dc.subjectMultiple myeloma
dc.subject.meshClinical Decision-Making
dc.subject.meshDisease Management
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMultiple Myeloma
dc.subject.meshNeoplasm, Residual
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.titleMaking clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC8369640.pdf
Size:
829.67 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen de las Nieves

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía